RT Journal Article
SR Electronic
T1 Unequal impact of the Covid-19 pandemic on excess deaths, life expectancy, and premature mortality across Spanish regions in 2020 and 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.29.21266617
DO 10.1101/2021.11.29.21266617
A1 Nazrul Islam
A1 Fernando J. García López
A1 Dmitri A. Jdanov
A1 Miguel Ángel Royo- Bordonada
A1 Kamlesh Khunti
A1 Sarah Lewington
A1 Ben Lacey
A1 Martin White
A1 Eva JA Morris
A1 María Victoria Zunzunegui
YR 2021
UL http://medrxiv.org/content/early/2021/11/29/2021.11.29.21266617.abstract
AB Spain is one of the most heavily affected countries by the Covid-19 pandemic. In this study, we estimated the regional inequalities in excess deaths and premature mortality in Spain. Between January 2020 and June 2021, an estimated 89,200 (men: 48,000; women: 41,200) excess deaths occurred in the 17 Spanish regions with a substantial variability (highest in Madrid: 22,000, lowest in Canary Islands: -210). Highest reductions in life expectancy at birth (e0) in 2020 were observed in Madrid (men: -3.48 years, women: -2.15), Castile La Mancha (men: -2.67, women: -2.30), and Castile and León (men: -2.00, women: -1.32). In the first six months of 2021, the highest reduction in e0 was observed in Valencian Community (men: -2.04, women: -1.63), Madrid (men: - 2.37), and Andalusia (men: -1.75; women: -1.43). In some Spanish regions, life expectancy at age 65 during the Covid-19 pandemic in 2020 was comparable to that observed as far back as 20 years ago.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding statement and statement of the independence of researchers from funders: This study did not receive any specific funding. NI receives salary support from the Nuffield Department of Population Health (NDPH), University of Oxford. BL acknowledges support from UK Biobank, the NIHR Oxford Biomedical Research Centre, and the BHF Centre of Research Excellence, Oxford). MW is supported by the Centre for Diet and Activity Research (CEDAR), a UK Clinical Research Collaboration (UKCRC) Public Health Research Centre of Excellence Funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, National Institute for Health Research (NIHR), and Wellcome Trust, under the auspices of the UKCRC. MW is also supported by the Medical Research Council (grant Nos MC_UU_12015/6 and MC_UU_00006/7). VMS & JDA were partially supported by the Basic Research Program of the National Research University Higher School of Economics. KK is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). Employers/sponsors had no role in the design, analysis, or dissemination of the study. The views expressed in this article are those of the authors and not necessarily those of the entities the authors are affiliated with and/or supported by.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was waived by the COMITE DE ETICA DE LA INVESTIGACION (No: CEI PI 77_2021) of Instituto de Salud Carlos III because all data analysed in this study were fully anonymised and aggregated without any identifiable information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnnual population data, and the weekly mortality data from first week of 2019 and to week 24 of 2021 are publicly available from the Instituto Nacional de Estadistica (https://www.ine.es/jaxiT3). We have obtained weekly data for 2015-2018 (for excess mortality), and monthly data (including infant mortality) for 2010-2020 (for life expectancy and years of life lost calculation) from Instituto Nacional de Estadistica with a small fee. These data could be obtained from Instituto Nacional de Estadistica (with a small fee), but we will make the data available on a public repository if this is approved by the Instituto Nacional de Estadistica.